Loading clinical trials...
Loading clinical trials...
An Open-Label Phase 1/2 Study of EBNK-001, an Allogeneic Natural Killer (NK) Cell Therapy Administered After Cyclophosphamide/Fludarabine Lymphodepletion With Low-Dose Interleukin-15, With or Without Pembrolizumab, in Participants With Advanced Solid Tumors
Conditions
Interventions
EBNK-001 + IL-15 + Pembrolizumab
Locations
1
China
District One Hospital
Beijing, Beijing Municipality, China
Start Date
February 1, 2026
Primary Completion Date
December 21, 2028
Completion Date
December 21, 2029
Last Updated
February 18, 2026
NCT04541381
NCT05671510
NCT06043817
NCT07549477
NCT06594926
NCT03137095
Lead Sponsor
Essen Biotech
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions